{ "instance": { "svra-20221231.htm": { "axisCustom": 0, "axisStandard": 28, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 588, "http://xbrl.sec.gov/dei/2022": 39 }, "contextCount": 188, "dts": { "calculationLink": { "local": [ "svra-20221231_cal.xml" ] }, "definitionLink": { "local": [ "svra-20221231_def.xml" ] }, "inline": { "local": [ "svra-20221231.htm" ] }, "labelLink": { "local": [ "svra-20221231_lab.xml" ] }, "presentationLink": { "local": [ "svra-20221231_pre.xml" ] }, "schema": { "local": [ "svra-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 680, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://www.savarapharma.com/20221231": 1, "http://xbrl.sec.gov/dei/2022": 4, "total": 10 }, "keyCustom": 93, "keyStandard": 302, "memberCustom": 41, "memberStandard": 35, "nsprefix": "svra", "nsuri": "http://www.savarapharma.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "10", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "11", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Short-term Investments", "menuCat": "Notes", "order": "12", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments", "shortName": "Short-term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Property and Equipment, Net", "menuCat": "Notes", "order": "13", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Debt Facility", "menuCat": "Notes", "order": "14", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacility", "shortName": "Debt Facility", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "15", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Stockholders\u2019 Equity", "menuCat": "Notes", "order": "16", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Commitments", "menuCat": "Notes", "order": "17", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Related Parties", "menuCat": "Notes", "order": "18", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "19", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "21", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "22", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Short-term Investments (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables", "shortName": "Short-term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Property and Equipment, Net (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Debt Facility (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityTables", "shortName": "Debt Facility (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "svra:ScheduleOfNetProceedsFromPrivatePlacementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Stockholders\u2019 Equity (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "svra:ScheduleOfNetProceedsFromPrivatePlacementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Commitments (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables", "shortName": "Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)", "menuCat": "Details", "order": "35", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Description of Business and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_ab11b2b2-7263-41aa-93ce-b582502062f8", "decimals": "INF", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "menuCat": "Details", "order": "36", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "lang": "en-US", "name": "svra:LiquidInvestmentsMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "svra:PrepaidContractedResearchAndDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail)", "menuCat": "Details", "order": "37", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail", "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "svra:PrepaidContractedResearchAndDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "svra:TaxCreditReceivablePolicyTextBlock", "div", "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_83602441-fc6b-465d-a5ba-54a131f93176", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Prepaid Expenses and Other Current Assets - Additional Information (Details)", "menuCat": "Details", "order": "38", "role": "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails", "shortName": "Prepaid Expenses and Other Current Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "svra:TaxCreditReceivablePolicyTextBlock", "div", "svra:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_83602441-fc6b-465d-a5ba-54a131f93176", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)", "menuCat": "Details", "order": "39", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Short-term Investments - Summary of Major Security and Type of Investments (Detail)", "menuCat": "Details", "order": "40", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail", "shortName": "Short-term Investments - Summary of Major Security and Type of Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Short-term Investments - Additional Information (Detail)", "menuCat": "Details", "order": "41", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetail", "shortName": "Short-term Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Property and Equipment, Net - Property and Equipment, Net (Detail)", "menuCat": "Details", "order": "42", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail", "shortName": "Property and Equipment, Net - Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Debt Facility - Additional Information (Detail)", "menuCat": "Details", "order": "43", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "shortName": "Debt Facility - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_893a87ba-0df1-452c-9d72-ebe53deeca1d", "decimals": null, "lang": "en-US", "name": "svra:LoanAgreementAmendmentDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Debt Facility - Carrying Value and Future Minimum Payments (Detail)", "menuCat": "Details", "order": "44", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail", "shortName": "Debt Facility - Carrying Value and Future Minimum Payments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_80376929-45be-43da-a26c-8256a0fa1abf", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Instruments (Detail)", "menuCat": "Details", "order": "45", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "shortName": "Fair Value Measurements - Summary of Fair Value of Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_80376929-45be-43da-a26c-8256a0fa1abf", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "menuCat": "Details", "order": "46", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "svra:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "menuCat": "Details", "order": "47", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "lang": null, "name": "svra:CommonStockAndPreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "svra:ScheduleOfNetProceedsFromPrivatePlacementTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_59644bb3-738a-4489-b7a5-2ad0beb7f0ed", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Stockholders' Equity - Summary of Net Proceeds from Private Placement (Detail)", "menuCat": "Details", "order": "48", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail", "shortName": "Stockholders' Equity - Summary of Net Proceeds from Private Placement (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "svra:ScheduleOfNetProceedsFromPrivatePlacementTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_02a85508-c852-40b7-8d82-b7a669403574", "decimals": "-3", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "svra:SummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "svra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Shareholders' Equity - Summary of Net Proceeds after Deducting Underwriting Discounts Commissions and Offering Expenses (Details)", "menuCat": "Details", "order": "49", "role": "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "shortName": "Shareholders' Equity - Summary of Net Proceeds after Deducting Underwriting Discounts Commissions and Offering Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "svra:SummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "svra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_249fa692-5d16-4793-b390-fc7abee39aef", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_249fa692-5d16-4793-b390-fc7abee39aef", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Stockholders' Equity - Summary of Company's Common Stock (Detail)", "menuCat": "Details", "order": "50", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySCommonStockDetail", "shortName": "Stockholders' Equity - Summary of Company's Common Stock (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "svra:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stockholders' Equity - Company's Shares of Common Stock Reserved for Issuance (Detail)", "menuCat": "Details", "order": "51", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail", "shortName": "Stockholders' Equity - Company's Shares of Common Stock Reserved for Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "svra:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_97327289-3136-4f34-81ec-c1dcfaa4e6b5", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Stockholders' Equity - Summary of Outstanding Warrants for Company's Common Stock (Detail)", "menuCat": "Details", "order": "52", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail", "shortName": "Stockholders' Equity - Summary of Outstanding Warrants for Company's Common Stock (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_314f3f5c-73d5-4fd1-b673-c352950ffcf8", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_84127420-1459-4579-a1b5-8cd02e51b6dd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Detail)", "menuCat": "Details", "order": "53", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail", "shortName": "Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_249fa692-5d16-4793-b390-fc7abee39aef", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "us-gaap:LesseeOperatingLeaseOptionToExtend", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Commitments - Additional Information (Detail)", "menuCat": "Details", "order": "54", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail", "shortName": "Commitments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:LesseeOperatingLeaseOptionToExtend", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Commitments - Schedule of Maturity Analysis of Annual Undiscounted Cash Flows Reconciled to Carrying Value of Operating Lease Liabilities (Detail)", "menuCat": "Details", "order": "55", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail", "shortName": "Commitments - Schedule of Maturity Analysis of Annual Undiscounted Cash Flows Reconciled to Carrying Value of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Commitments - Schedule of Lease Cost and Other Information (Detail)", "menuCat": "Details", "order": "56", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfLeaseCostAndOtherInformationDetail", "shortName": "Commitments - Schedule of Lease Cost and Other Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LongTermPurchaseCommitmentTextBlock", "div", "us-gaap:CommitmentsAndContingenciesPolicyTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Commitments - Schedule of Manufacturing Commitments and Contingencies (Details)", "menuCat": "Details", "order": "57", "role": "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails", "shortName": "Commitments - Schedule of Manufacturing Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LongTermPurchaseCommitmentTextBlock", "div", "us-gaap:CommitmentsAndContingenciesPolicyTextBlock", "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Related Parties - Additional Information (Detail)", "menuCat": "Details", "order": "58", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "shortName": "Related Parties - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_fc1636b9-fc7e-47b2-9a86-68a7cd50a491", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "menuCat": "Details", "order": "59", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_e3340ef8-3a17-4c91-b79e-e9ee2f27ca7c", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_bcdcf89e-c787-4000-bb33-95d399ca07e4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted to Employees (Detail)", "menuCat": "Details", "order": "60", "role": "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "shortName": "Stock-Based Compensation - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted to Employees (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_bcdcf89e-c787-4000-bb33-95d399ca07e4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_84127420-1459-4579-a1b5-8cd02e51b6dd", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and RSU Activity (Detail)", "menuCat": "Details", "order": "61", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity and RSU Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense included in Accompanying Statements of Operations and Comprehensive Loss (Detail)", "menuCat": "Details", "order": "62", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail", "shortName": "Stock-Based Compensation - Stock-based Compensation Expense included in Accompanying Statements of Operations and Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)", "menuCat": "Details", "order": "63", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail", "shortName": "Income Taxes - Components of Loss Before Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Income Taxes - Additional Information (Detail)", "menuCat": "Details", "order": "64", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Income Taxes - Components of Benefit for Income Taxes (Detail)", "menuCat": "Details", "order": "65", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail", "shortName": "Income Taxes - Components of Benefit for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Income Taxes - Reconciliation of Expected Income Tax (Detail)", "menuCat": "Details", "order": "66", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail", "shortName": "Income Taxes - Reconciliation of Expected Income Tax (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesOther", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)", "menuCat": "Details", "order": "67", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_78a081b1-f108-4275-a28c-fb40c995a754", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesOther", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities (Detail)", "menuCat": "Details", "order": "68", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail", "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Net Loss Per Share - Reconciles Basic Earnings Per Share and Diluted Earnings Per Share of Common Stock (Detail)", "menuCat": "Details", "order": "69", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail", "shortName": "Net Loss Per Share - Reconciles Basic Earnings Per Share and Diluted Earnings Per Share of Common Stock (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "svra:LiquidityPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_efd8144f-347b-4c0f-9964-260e7cf22c14", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Subsequent Events (Additional Information) (Details)", "menuCat": "Details", "order": "70", "role": "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3e0b4433-7dcb-40d1-a0ef-76abcd44726d", "decimals": "INF", "lang": null, "name": "svra:NumberOfAdditionalSquareFeetLeasedUnderOperatingLease", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Description of Business and Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation", "shortName": "Description of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "svra-20221231.htm", "contextRef": "C_3cadb113-a6d5-4dbd-9987-b640d22b1e77", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 77, "tag": { "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan [Member]" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r711" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "verboseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r712" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "CEO [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r237", "r492", "r493", "r496", "r497", "r573", "r663", "r745", "r748", "r749" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r237", "r492", "r493", "r496", "r497", "r573", "r663", "r745", "r748", "r749" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r235", "r236", "r355", "r383", "r669", "r671" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r339", "r340", "r341", "r342", "r408", "r607", "r636", "r664", "r665", "r687", "r693", "r702", "r750", "r802", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r339", "r340", "r341", "r342", "r408", "r607", "r636", "r664", "r665", "r687", "r693", "r702", "r750", "r802", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r299", "r608", "r688", "r700", "r743", "r744", "r752", "r810" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r299", "r608", "r688", "r700", "r743", "r744", "r752", "r810" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r339", "r340", "r341", "r342", "r400", "r408", "r438", "r439", "r440", "r583", "r607", "r636", "r664", "r665", "r687", "r693", "r702", "r742", "r750", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r339", "r340", "r341", "r342", "r400", "r408", "r438", "r439", "r440", "r583", "r607", "r636", "r664", "r665", "r687", "r693", "r702", "r742", "r750", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r235", "r236", "r355", "r383", "r670", "r671" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r300", "r301", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r689", "r701", "r752" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r300", "r301", "r649", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r689", "r701", "r752" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r730", "r798" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "State of Texas [Member]" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_AccruedContractedResearchAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued contracted research and development costs.", "label": "Accrued Contracted Research And Development Costs", "terseLabel": "Accrued contracted research and development costs" } } }, "localname": "AccruedContractedResearchAndDevelopmentCosts", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "svra_AccruedGeneralAndAdministrativeCosts": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued general and administrative costs.", "label": "Accrued General And Administrative Costs", "terseLabel": "Accrued general and administrative costs" } } }, "localname": "AccruedGeneralAndAdministrativeCosts", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "svra_AccruedLeaseLiability": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued lease liability.", "label": "Accrued Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "AccruedLeaseLiability", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "svra_ActivePharmaceuticalIngredientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Active Pharmaceutical Ingredients.", "label": "Active Pharmaceutical Ingredients [Member]", "terseLabel": "Active Pharmaceutical Ingredients [Member]" } } }, "localname": "ActivePharmaceuticalIngredientsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_AdjustmentToAdditionalPaidInCapitalRepurchaseOfPreFundedWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment To Additional Paid In Capital Repurchase Of Pre-Funded Warrants.", "label": "Adjustment To Additional Paid In Capital Repurchase Of Pre Funded Warrants", "negatedLabel": "Repurchase of outstanding pre-funded warrants" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalRepurchaseOfPreFundedWarrants", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "svra_AdjustmentsToAdditionalPaidInCapitalClosingCostsForPreviousIssuanceOfSecuritiesInPrivatePlacement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital, closing costs for previous issuance of securities in private placement.", "label": "Adjustments To Additional Paid In Capital Closing Costs For Previous Issuance Of Securities In Private Placement", "negatedLabel": "Closing costs for previous issuance of securities in private placement" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalClosingCostsForPreviousIssuanceOfSecuritiesInPrivatePlacement", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "svra_AfterFirstAndBeforeSecondAnniversaryClosingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "After first and before second anniversary closing date.", "label": "After First and Before Second Anniversary Closing Date [Member]", "terseLabel": "After First And Before Second Anniversary Closing Date" } } }, "localname": "AfterFirstAndBeforeSecondAnniversaryClosingDateMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_AgreementTerminationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement termination date.", "label": "Agreement Termination Date", "terseLabel": "Termination of agreement" } } }, "localname": "AgreementTerminationDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_AmortizedCostAndFairValueDebtSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortized cost and fair value debt securities.", "label": "Amortized Cost And Fair Value Debt Securities [Abstract]" } } }, "localname": "AmortizedCostAndFairValueDebtSecuritiesAbstract", "nsuri": "http://www.savarapharma.com/20221231", "xbrltype": "stringItemType" }, "svra_AprilTwoThousandSeventeenWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 2017 warrants.", "label": "April Two Thousand Seventeen Warrants [Member]", "terseLabel": "April 2017 Warrants [Member]" } } }, "localname": "AprilTwoThousandSeventeenWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "svra_AutoimmunePulmonaryAlveolarProteinosisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Autoimmune pulmonary alveolar proteinosis.", "label": "Autoimmune Pulmonary Alveolar Proteinosis [Member]", "terseLabel": "aPAP [Member]" } } }, "localname": "AutoimmunePulmonaryAlveolarProteinosisMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_BainCapitalLifeScienceInvestorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bain capital life science investors, llc.", "label": "Bain Capital Life Science Investors L L C [Member]", "terseLabel": "Bain [Member]" } } }, "localname": "BainCapitalLifeScienceInvestorsLLCMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_BeforeFirstAnniversaryClosingDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Before first anniversary closing date.", "label": "Before First Anniversary Closing Date [Member]", "terseLabel": "Before First Anniversary Closing Date [Member]" } } }, "localname": "BeforeFirstAnniversaryClosingDateMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_CashAndCashEquivalentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents fair value disclosure.", "label": "Cash And Cash Equivalents Fair Value Disclosure [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosureAbstract", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "svra_ChangeInOwnershipInterestPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in ownership interest period.", "label": "Change In Ownership Interest Period", "terseLabel": "Change in ownership interest period" } } }, "localname": "ChangeInOwnershipInterestPeriod", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "svra_ChiefFinancialOfficerAndChiefMedicalOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Financial Officer and Chief Medical Officer.", "label": "Chief Financial Officer And Chief Medical Officer [Member]", "terseLabel": "Chief Financial Officer (\u201cCFO\u201d) and Chief Medical Officer (\u201cCMO\u201d) [Member]" } } }, "localname": "ChiefFinancialOfficerAndChiefMedicalOfficerMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_ClassOfWarrantFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant five.", "label": "Class Of Warrant Five [Member]", "terseLabel": "Exercise Price Five [Member]" } } }, "localname": "ClassOfWarrantFiveMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "domainItemType" }, "svra_ClassOfWarrantFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant four.", "label": "Class Of Warrant Four [Member]", "terseLabel": "Exercise Price Four [Member]" } } }, "localname": "ClassOfWarrantFourMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "domainItemType" }, "svra_ClassOfWarrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant one.", "label": "Class Of Warrant One [Member]", "terseLabel": "Exercise Price One [Member]" } } }, "localname": "ClassOfWarrantOneMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "domainItemType" }, "svra_ClassOfWarrantOrRightsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights expiration period.", "label": "Class Of Warrant Or Rights Expiration Period", "terseLabel": "Expiration Date" } } }, "localname": "ClassOfWarrantOrRightsExpirationPeriod", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "gYearMonthItemType" }, "svra_ClassOfWarrantOrRightsExpirationPeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights expiration period description.", "label": "Class Of Warrant Or Rights Expiration Period Description", "terseLabel": "Expiration Date" } } }, "localname": "ClassOfWarrantOrRightsExpirationPeriodDescription", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "stringItemType" }, "svra_ClassOfWarrantThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant three.", "label": "Class Of Warrant Three [Member]", "terseLabel": "Exercise Price Three [Member]" } } }, "localname": "ClassOfWarrantThreeMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "domainItemType" }, "svra_ClassOfWarrantTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant two.", "label": "Class Of Warrant Two [Member]", "terseLabel": "Exercise Price Two [Member]" } } }, "localname": "ClassOfWarrantTwoMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "domainItemType" }, "svra_CliffVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cliff vesting.", "label": "Cliff Vesting [Member]", "terseLabel": "Cliff Vest [Member]" } } }, "localname": "CliffVestingMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_CommonStockAggregateOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock aggregate offering price.", "label": "Common Stock Aggregate Offering Price", "terseLabel": "Amount available to sell under equity program" } } }, "localname": "CommonStockAggregateOfferingPrice", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_CommonStockAndPreFundedPIPEWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock and pre-funded PIPE warrants.", "label": "Common Stock And Pre Funded P I P E Warrants [Member]", "terseLabel": "Common Stock and Pre-Funded PIPE Warrants [Member]" } } }, "localname": "CommonStockAndPreFundedPIPEWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail" ], "xbrltype": "domainItemType" }, "svra_CommonStockAndPreferredStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock and preferred stock shares authorized.", "label": "Common Stock And Preferred Stock Shares Authorized", "terseLabel": "Common and preferred stock, shares authorized" } } }, "localname": "CommonStockAndPreferredStockSharesAuthorized", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "svra_CommonStockPreFundedWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock pre funded warrants exercise price.", "label": "Common Stock Pre Funded Warrants Exercise Price", "terseLabel": "Common Stock pre funded warrants exercise price" } } }, "localname": "CommonStockPreFundedWarrantsExercisePrice", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "svra_CommonStockPreFundedWarrantsPerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock pre funded warrants per warrant .", "label": "Common Stock Pre Funded Warrants Per Warrant", "terseLabel": "Common Stock pre funded warrants per warrant" } } }, "localname": "CommonStockPreFundedWarrantsPerWarrant", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "svra_CommonStockPreFundedWarrantsToPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock pre-funded warrants to purchase.", "label": "Common Stock Pre Funded Warrants To Purchase", "terseLabel": "Common stock, pre-funded warrants to purchase" } } }, "localname": "CommonStockPreFundedWarrantsToPurchase", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "sharesItemType" }, "svra_CommonStockSalesAgreementEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock sales agreement effective date.", "label": "Common Stock Sales Agreement Effective Date", "terseLabel": "Common stock sales agreement, effective date" } } }, "localname": "CommonStockSalesAgreementEffectiveDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_ContingentMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent milestone payments.", "label": "Contingent Milestone Payments", "verboseLabel": "Achievement of various development activities and regulatory approval of nebulizer utilized to administer molgramostim" } } }, "localname": "ContingentMilestonePayments", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "svra_DebtInstrumentCovenantsCashAndCashEquivalentsThresholdLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument covenants, cash and cash equivalents threshold limit.", "label": "Debt instrument covenants cash and cash equivalents threshold limit", "terseLabel": "Debt instrument covenants cash and cash equivalents threshold limit" } } }, "localname": "DebtInstrumentCovenantsCashAndCashEquivalentsThresholdLimit", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_DebtInstrumentDateOfFirstRequiredPaymentUponMeetingTrialRequirement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument date of first required payment upon meeting trial requirement.", "label": "Debt Instrument Date Of First Required Payment Upon Meeting Trial Requirement", "terseLabel": "Debt instrument, date of first required payment upon meeting trial requirement" } } }, "localname": "DebtInstrumentDateOfFirstRequiredPaymentUponMeetingTrialRequirement", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_DebtInstrumentPrepaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment fee percentage.", "label": "Debt Instrument Prepayment Fee Percentage", "terseLabel": "Prepayment fee percentage" } } }, "localname": "DebtInstrumentPrepaymentFeePercentage", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_DebtInstrumentPrincipalAndInterestPaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument principal and interest payment period.", "label": "Debt Instrument Principal And Interest Payment Period", "terseLabel": "Debt instrument principal and interest payment period" } } }, "localname": "DebtInstrumentPrincipalAndInterestPaymentPeriod", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "svra_DecemberTwoThousandEighteenWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2018 Warrants.", "label": "December Two Thousand Eighteen Warrants [Member]", "terseLabel": "December 2018 Warrants [Member]" } } }, "localname": "DecemberTwoThousandEighteenWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "svra_DecreaseInMilestonePaymentRelatedToTheRemovalOfNebulizerSystem": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in milestone payment related to the removal of Nebulizer system.", "label": "Decrease In Milestone Payment Related To The Removal Of Nebulizer System", "terseLabel": "Decrease in milestone payment related to the removal of Nebulizer System" } } }, "localname": "DecreaseInMilestonePaymentRelatedToTheRemovalOfNebulizerSystem", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredFederalForeignIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred federal foreign income tax expense (benefit).", "label": "Deferred Federal Foreign Income Tax Expense Benefit", "totalLabel": "Total deferred" } } }, "localname": "DeferredFederalForeignIncomeTaxExpenseBenefit", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredTaxAssetsAccruedLiabilitiesAndOther": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets accrued Llabilities and other.", "label": "Deferred Tax Assets Accrued Liabilities And Other", "terseLabel": "Accrued liabilities & other" } } }, "localname": "DeferredTaxAssetsAccruedLiabilitiesAndOther", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredTaxAssetsAmortization": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets amortization.", "label": "Deferred Tax Assets Amortization", "terseLabel": "Amortization" } } }, "localname": "DeferredTaxAssetsAmortization", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets liabilities net before valuation allowance.", "label": "Deferred Tax Assets Liabilities Net Before Valuation Allowance", "totalLabel": "Subtotal" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredTaxAssetsOperatingLossCarryForwardsExpirationBeginningYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss carry forwards expiration beginning year.", "label": "Deferred Tax Assets Operating Loss Carry Forwards Expiration Beginning Year", "terseLabel": "Operating loss carry forwards expiration beginning Year" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryForwardsExpirationBeginningYear", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "svra_DeferredTaxAssetsOperatingLossCarryForwardsWithExpirationDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss carry forwards with expiration date.", "label": "Deferred Tax Assets Operating Loss Carry Forwards With Expiration Date", "terseLabel": "Operating loss carry forwards with expiration date" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryForwardsWithExpirationDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredTaxAssetsOperatingLossCarryForwardsWithNoExpirationDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss carry forwards with no expiration date.", "label": "Deferred Tax Assets Operating Loss Carry Forwards With No Expiration Date", "terseLabel": "Operating loss carry forwards with no expiration date" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryForwardsWithNoExpirationDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredTaxAssetsOperatingLossCarryforwardsLimitation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss carryforwards limitation.", "label": "Deferred Tax Assets Operating Loss Carryforwards Limitation", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsLimitation", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_DeferredTaxAssetsTaxCreditCarryforwardLimitation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax credit carryforward limitation.", "label": "Deferred Tax Assets tax Credit Carryforward Limitation", "terseLabel": "Research and orphan drug tax credit carry forwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardLimitation", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_DepositsAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits and other assets current.", "label": "Deposits And Other Assets Current", "terseLabel": "Deposits and other" } } }, "localname": "DepositsAndOtherAssetsCurrent", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "svra_DescriptionOfBusinessAndBasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business and basis of presentation.", "label": "Description Of Business And Basis Of Presentation [Line Items]", "terseLabel": "Description Of Business And Basis Of Presentation [Line Items]" } } }, "localname": "DescriptionOfBusinessAndBasisOfPresentationLineItems", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_DescriptionOfBusinessAndBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business and basis of presentation.", "label": "Description Of Business And Basis Of Presentation [Table]", "terseLabel": "Description Of Business And Basis Of Presentation [Table]" } } }, "localname": "DescriptionOfBusinessAndBasisOfPresentationTable", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwardLimitation": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation net operating loss carryforward limitation.", "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Carryforward Limitation", "terseLabel": "Sec. 382 Limitation", "verboseLabel": "Valuation allowance decrease due to Section 382 limited NOLs and credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwardLimitation", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "svra_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees.", "label": "Employees [Member]", "terseLabel": "Employees [Member]" } } }, "localname": "EmployeesMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail" ], "xbrltype": "domainItemType" }, "svra_EmploymentAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment agreement description.", "label": "Employment Agreement Description", "terseLabel": "Employment agreement description" } } }, "localname": "EmploymentAgreementDescription", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_EndOfTermChargeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End of term charge.", "label": "End Of Term Charge [Member]", "terseLabel": "End of Term Charge [Member]" } } }, "localname": "EndOfTermChargeMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_EstimatedParexelServiceFeesAndPassThroughExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated parexel service fees and pass-through expenses.", "label": "Estimated Parexel Service Fees And Pass Through Expenses", "terseLabel": "Estimated service fees and pass-through expenses" } } }, "localname": "EstimatedParexelServiceFeesAndPassThroughExpenses", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_EvercoreGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evercore group llc member.", "label": "Evercore Group L L C [Member]", "terseLabel": "Evercore Group L.L.C., [Member]", "verboseLabel": "Evercore [Member]" } } }, "localname": "EvercoreGroupLLCMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_FairValueAssetsLevel1ToLevel2TransfersAmounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value Assets Level1 To Level2 Transfers Amounts", "label": "Fair Value Assets Level1 To Level2 Transfers Amounts", "terseLabel": "Fair value, assets, level 1 to level 2 transfers, amount" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmounts", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_FairValueAssetsLevel2ToLevel1TransfersAmounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value Assets Level2 To Level1 Transfers Amounts", "label": "Fair Value Assets Level2 To Level1 Transfers Amounts", "terseLabel": "Fair value, assets, level 2 to level 1 transfers, amount" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmounts", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_HCWainwrightAndCoLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HC Wainwright and Co LLC.", "label": "H C Wainwright And Co L L C [Member]", "terseLabel": "H.C. Wainwright & Co., LLC [Member]" } } }, "localname": "HCWainwrightAndCoLLCMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_InProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "In-process research and development.", "label": "In Process Research And Development", "terseLabel": "In-process R&D", "verboseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopment", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "svra_IncomeTaxReconciliationForeignDeferredTaxAssetTrueUp": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation foreign deferred tax asset true up.", "label": "Income Tax Reconciliation Foreign Deferred tax Asset True Up", "terseLabel": "Foreign deferred tax asset - true up" } } }, "localname": "IncomeTaxReconciliationForeignDeferredTaxAssetTrueUp", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "svra_IncomeTaxReconciliationImputedInterest": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation imputed interest.", "label": "Income Tax Reconciliation Imputed Interest", "terseLabel": "Imputed interest" } } }, "localname": "IncomeTaxReconciliationImputedInterest", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "svra_IncomeTaxReconciliationPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation permanent differences.", "label": "Income Tax Reconciliation Permanent Differences", "terseLabel": "Permanent differences" } } }, "localname": "IncomeTaxReconciliationPermanentDifferences", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "svra_IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accounts payable and accrued expenses and other current liabilities.", "label": "Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities", "terseLabel": "Accounts payable and accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "svra_IncreaseDecreaseInLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in long term liabilities.", "label": "Increase Decrease In Long Term Liabilities", "terseLabel": "Long-term liabilities" } } }, "localname": "IncreaseDecreaseInLongTermLiabilities", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "svra_IncreaseDecreaseInNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in noncurrent assets.", "label": "Increase Decrease In Noncurrent Assets", "negatedLabel": "Non-current assets" } } }, "localname": "IncreaseDecreaseInNoncurrentAssets", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "svra_IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in process research and development due to foreign currency translation.", "label": "Increase Decrease In Process Research And Development Due To Foreign Currency Translation", "terseLabel": "Increase (decrease) in carrying value of IPR&D due to foreign currency translation" } } }, "localname": "IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_InterestOnlyExtensionCashPercentageOfOutstandingPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest only extension, cash percentage of outstanding principal.", "label": "Interest only extension cash percentage of outstanding principal", "terseLabel": "Interest only extension cash percentage of outstanding principal" } } }, "localname": "InterestOnlyExtensionCashPercentageOfOutstandingPrincipal", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_IssuanceOfCommonStockForSettlementOfRestrictedStockUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for settlement of restricted stock units.", "label": "Issuance Of Common Stock For Settlement Of Restricted Stock Units", "terseLabel": "Issuance of common stock for settlement of RSUs" } } }, "localname": "IssuanceOfCommonStockForSettlementOfRestrictedStockUnits", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "svra_IssuanceOfCommonStockUponAtTheMarketOfferingNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon at the market offering net.", "label": "Issuance Of Common Stock Upon At The Market Offering Net", "terseLabel": "Issuance of common stock upon at the market offerings, net" } } }, "localname": "IssuanceOfCommonStockUponAtTheMarketOfferingNet", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "svra_IssuanceOfCommonStockUponAtTheMarketOfferingNetShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon at the market offering net shares.", "label": "Issuance Of Common Stock Upon At The Market Offering Net Shares", "terseLabel": "Issuance of common stock upon at The market offering, net, shares" } } }, "localname": "IssuanceOfCommonStockUponAtTheMarketOfferingNetShares", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "svra_JuneTwoThousandSeventeenWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2017 warrants.", "label": "June Two Thousand Seventeen Warrants [Member]", "terseLabel": "June 2017 Warrants [Member]" } } }, "localname": "JuneTwoThousandSeventeenWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "svra_LeaseAgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease agreement date.", "label": "Lease Agreement Date", "terseLabel": "Lease agreement date" } } }, "localname": "LeaseAgreementDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_LeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "localname": "LeaseCommencementDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_LeaseTerminationFeePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease termination fee paid.", "label": "Lease Termination Fee Paid", "terseLabel": "Lease termination fee paid" } } }, "localname": "LeaseTerminationFeePaid", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_LicenseAgreementIncreaseDecreaseInForeignCurrencyExchangeRates": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License agreement increase decrease in foreign currency exchange rates.", "label": "License Agreement Increase Decrease In Foreign Currency Exchange Rates", "terseLabel": "Change in foreign currency exchange rates" } } }, "localname": "LicenseAgreementIncreaseDecreaseInForeignCurrencyExchangeRates", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_LicenseAgreementMilestonePaymentReceivableRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License agreement milestone payment receivable revenue recognized.", "label": "License Agreement Milestone Payment Receivable Revenue Recognized", "terseLabel": "Milestone payment receivable revenue recognized" } } }, "localname": "LicenseAgreementMilestonePaymentReceivableRevenueRecognized", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_LicenseAgreementMilestonePaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License agreement, milestone payment received.", "label": "License Agreement Milestone Payment Received", "terseLabel": "Receipt of milestone payment" } } }, "localname": "LicenseAgreementMilestonePaymentReceived", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_LicenseAgreementTerminationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement termination date.", "label": "License Agreement Termination Date", "terseLabel": "License agreement termination date" } } }, "localname": "LicenseAgreementTerminationDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_LiquidInvestmentsMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquid investments maturity period.", "label": "Liquid Investments Maturity Period", "terseLabel": "Cash and cash equivalents with original maturities" } } }, "localname": "LiquidInvestmentsMaturityPeriod", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_LiquidityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity.", "label": "Liquidity Policy [Text Block]", "terseLabel": "Liquidity" } } }, "localname": "LiquidityPolicyTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "svra_LoanAgreementAmendmentDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan agreement amendment date.", "label": "Loan Agreement Amendment Date", "terseLabel": "Loan agreement amendment date" } } }, "localname": "LoanAgreementAmendmentDate", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_LoanAgreementAmendmentDateOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan agreement amendment date one.", "label": "Loan Agreement Amendment Date One", "terseLabel": "Loan agreement amendment date one" } } }, "localname": "LoanAgreementAmendmentDateOne", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_LoanAgreementAmendmentDateThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan agreement amendment date three.", "label": "Loan Agreement Amendment Date Three", "terseLabel": "Loan agreement amendment date three" } } }, "localname": "LoanAgreementAmendmentDateThree", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_LoanAgreementAmendmentDateTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan agreement amendment date two.", "label": "Loan Agreement Amendment Date Two", "terseLabel": "Loan agreement amendment date two" } } }, "localname": "LoanAgreementAmendmentDateTwo", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "svra_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement [Member]" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_MilestoneRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone revenue.", "label": "Milestone Revenue Policy [Text Block]", "terseLabel": "Milestone Revenue" } } }, "localname": "MilestoneRevenuePolicyTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "svra_MilestoneWarrantRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone warrant repurchase.", "label": "Milestone Warrant Repurchase [Member]" } } }, "localname": "MilestoneWarrantRepurchaseMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_MilestoneWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone warrants.", "label": "Milestone Warrants [Member]", "terseLabel": "Milestone Warrants [Member]" } } }, "localname": "MilestoneWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail" ], "xbrltype": "domainItemType" }, "svra_MinimumPercentagePointsChangeInOwnershipInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage point change in ownership interest.", "label": "Minimum Percentage Points Change In Ownership Interest", "terseLabel": "Change in ownership interest, percentage points" } } }, "localname": "MinimumPercentagePointsChangeInOwnershipInterest", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_NebulizerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nebulizer.", "label": "Nebulizer [Member]", "terseLabel": "Nebulizer [Member]", "verboseLabel": "Molgramostim Nebulizer Manufacturer [Member]" } } }, "localname": "NebulizerMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net proceeds after deducting underwriting discounts commissions and offering expenses.", "label": "Net Proceeds After Deducting Underwriting Discounts Commissions And Offering Expenses", "terseLabel": "Net proceeds after deducting underwriting discounts commissions and offering expenses", "totalLabel": "Net proceeds" } } }, "localname": "NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_NonEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-employees.", "label": "Non Employees [Member]", "terseLabel": "Non-Employees [Member]" } } }, "localname": "NonEmployeesMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_NonvestedRestrictedSharesAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nonvested restricted shares and restricted stock units.", "label": "Nonvested Restricted Shares And Restricted Stock Units [Member]", "terseLabel": "Nonvested Restricted Shares and Restricted Stock Units [Member]" } } }, "localname": "NonvestedRestrictedSharesAndRestrictedStockUnitsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "domainItemType" }, "svra_NumberOfAdditionalSquareFeetLeasedUnderOperatingLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional square feet leased under operating lease.", "label": "Number of Additional Square Feet Leased under Operating Lease", "terseLabel": "Number of additional square feet leased" } } }, "localname": "NumberOfAdditionalSquareFeetLeasedUnderOperatingLease", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "svra_NumberOfSquareFeetsLeasedUnderOperatingLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of square feets leased under operating lease.", "label": "Number of Square Feets Leased under Operating Lease", "terseLabel": "Number of square feets leased" } } }, "localname": "NumberOfSquareFeetsLeasedUnderOperatingLease", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "svra_NumberOfWarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants expired.", "label": "Number of Warrants Expired", "terseLabel": "Number of warrants expired" } } }, "localname": "NumberOfWarrantsExpired", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "svra_OperatingLeaseTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease termination period", "label": "Operating Lease Termination Period", "terseLabel": "Lease termination period" } } }, "localname": "OperatingLeaseTerminationPeriod", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_OtherAssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other assets fair value disclosure.", "label": "Other Assets Fair Value Disclosure [Abstract]", "terseLabel": "Other assets:" } } }, "localname": "OtherAssetsFairValueDisclosureAbstract", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "svra_OtherThanStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other than stock options.", "label": "Other Than Stock Options [Member]", "terseLabel": "Other Than Stock Option [Member]" } } }, "localname": "OtherThanStockOptionsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_PALeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PA lease.", "label": "P A Lease [Member]", "terseLabel": "PA Lease" } } }, "localname": "PALeaseMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_PaidInKindInterestIncomeExpense": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Paid in kind interest (income) expense.", "label": "Paid In Kind Interest Income Expense", "terseLabel": "Non-cash interest income" } } }, "localname": "PaidInKindInterestIncomeExpense", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "svra_PatentsAndIntellectualPropertyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents and intellectual property.", "label": "Patents And Intellectual Property Policy [Text Block]", "terseLabel": "Patents and Intellectual Property" } } }, "localname": "PatentsAndIntellectualPropertyPolicyTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "svra_PaymentUponAchievementOfCertainMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment upon achievement of certain milestones.", "label": "Payment Upon Achievement Of Certain Milestones", "terseLabel": "Achievement of certain milestones related to validation of API and regulatory approval of molgramostim" } } }, "localname": "PaymentUponAchievementOfCertainMilestones", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "svra_PercentageIncreaseInShareholdersOwnershipInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in shareholders ownership interest.", "label": "Percentage Increase In Shareholders Ownership Interest", "terseLabel": "Increase in shareholders ownership interest, percentage" } } }, "localname": "PercentageIncreaseInShareholdersOwnershipInterest", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_PercentageOfObligationToPayClosingFeesAndFinalPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of obligation to pay closing fees and final payment.", "label": "Percentage of Obligation To Pay Closing Fees And Final Payment", "terseLabel": "Percentage of obligation to pay closing fees and final payment" } } }, "localname": "PercentageOfObligationToPayClosingFeesAndFinalPayment", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_PercentageOfTargetBonusToBePaidUponTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of target bonus to be paid upon termination.", "label": "Percentage Of Target Bonus To Be Paid Upon Termination", "terseLabel": "Percentage of target bonus to be paid upon termination" } } }, "localname": "PercentageOfTargetBonusToBePaidUponTermination", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_PercentageOfUnpaidBonusToBePaidUponTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of unpaid bonus to be paid upon termination.", "label": "Percentage Of Unpaid Bonus To Be Paid Upon Termination", "terseLabel": "Percentage of unpaid bonus to be paid upon termination other than for cause or for good reason" } } }, "localname": "PercentageOfUnpaidBonusToBePaidUponTermination", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_PreFundedPIPEWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-funded PIPE warrants.", "label": "Pre Funded P I P E Warrants [Member]", "terseLabel": "Pre-Funded PIPE Warrants [Member]" } } }, "localname": "PreFundedPIPEWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "svra_PrepaidContractedResearchAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid contracted research and development costs.", "label": "Prepaid Contracted Research And Development Costs", "terseLabel": "Prepaid contracted research and development costs" } } }, "localname": "PrepaidContractedResearchAndDevelopmentCosts", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "svra_PrepaidExpensesAndOtherCurrentAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Line Items]", "terseLabel": "Prepaid Expenses And Other Current Assets [Line Items]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsLineItems", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "svra_PrepaidExpensesAndOtherCurrentAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Table]", "terseLabel": "Prepaid Expenses And Other Current Assets [Table]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTable", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "svra_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "svra_PrepaidResearchAndDevelopmentTaxCreditReceivable": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development tax credit receivable.", "label": "Prepaid Research And Development Tax Credit Receivable", "terseLabel": "R&D tax credit receivable" } } }, "localname": "PrepaidResearchAndDevelopmentTaxCreditReceivable", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "svra_PrepaymentFeeAfterTwentyFourMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment fee after twenty four months.", "label": "Prepayment Fee After Twenty Four Months [Member]", "terseLabel": "Prepayment Fee Thereafter [Member]" } } }, "localname": "PrepaymentFeeAfterTwentyFourMonthsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_PrepaymentFeeDuringThirteenToTwentyFourMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment fee during thirteen to twenty four months.", "label": "Prepayment Fee During Thirteen To Twenty Four Months [Member]", "terseLabel": "Prepayment Fee 13-24 Months [Member]" } } }, "localname": "PrepaymentFeeDuringThirteenToTwentyFourMonthsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails": { "order": 0.0, "parentTag": "svra_NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and pre funded warrants.", "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants", "terseLabel": "Total common stock and pre-funded warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "svra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and pre-funded warrants in public offering, net of offering costs.", "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs", "terseLabel": "Issuance of common stock and pre-funded warrants in public offering, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "svra_ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrantsNet": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock upon exercise of warrants, net.", "label": "Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants Net", "terseLabel": "Issuance of common stock upon exercise of warrants, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrantsNet", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "svra_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment useful life and values.", "label": "Property Plant And Equipment Useful Life And Values [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract", "nsuri": "http://www.savarapharma.com/20221231", "xbrltype": "stringItemType" }, "svra_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public offering.", "label": "Public Offering [Member]", "terseLabel": "Public Offering of Common Stock [Member]", "verboseLabel": "Public Offering [Member]" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "svra_PurchasePriceOfCommonStockCoveredByStockOptionAsPercentageOfFairMarketValueOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock covered by stock option as percentage of fair market value of common stock.", "label": "Purchase Price Of Common Stock Covered By Stock Option As Percentage Of Fair Market Value Of Common Stock", "terseLabel": "Purchase price of shares of common stock" } } }, "localname": "PurchasePriceOfCommonStockCoveredByStockOptionAsPercentageOfFairMarketValueOfCommonStock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_RatioOfStockOptionsOrStockAppreciationRightsGrantedAgainstSharesAvailableForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio of stock options or stock appreciation rights granted against shares available for issuance.", "label": "Ratio Of Stock Options Or Stock Appreciation Rights Granted Against Shares Available For Issuance", "terseLabel": "Ratio of stock options or stock appreciation rights granted against shares available for issuance" } } }, "localname": "RatioOfStockOptionsOrStockAppreciationRightsGrantedAgainstSharesAvailableForIssuance", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "svra_ReductionOfOperatingLeaseLiabilitiesDueToTerminationOfLeaseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction of operating lease liabilities due to termination of lease agreement.", "label": "Reduction of Operating Lease Liabilities Due to Termination of Lease Agreement", "terseLabel": "Reduction of operating lease liabilities" } } }, "localname": "ReductionOfOperatingLeaseLiabilitiesDueToTerminationOfLeaseAgreement", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_ReductionOfRightOfUseOperatingLeaseAssetsDueToTerminationOfLeaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction of right-of-use operating lease assets due to termination of lease agreement.", "label": "Reduction of Right-of-use Operating Lease Assets Due to Termination of Lease Agreement", "terseLabel": "Reduction of right-of-use operating lease assets" } } }, "localname": "ReductionOfRightOfUseOperatingLeaseAssetsDueToTerminationOfLeaseAgreement", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_RepurchaseOfSharesForMinimumTaxWithholdings": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repurchase of shares for minimum tax withholdings.", "label": "Repurchase of shares for minimum tax withholdings", "negatedLabel": "Repurchase of shares for minimum tax withholdings" } } }, "localname": "RepurchaseOfSharesForMinimumTaxWithholdings", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "svra_ResearchAndDevelopmentEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development equipment.", "label": "Research And Development Equipment [Member]", "terseLabel": "Research and Development Equipment [Member]" } } }, "localname": "ResearchAndDevelopmentEquipmentMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "svra_ResearchAndDevelopmentExpenseForTermination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense for termination.", "label": "Research And Development Expense For Termination", "verboseLabel": "Research and development expense for termination" } } }, "localname": "ResearchAndDevelopmentExpenseForTermination", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_ResearchAndDevelopmentTaxCreditReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development tax credit receivable.", "label": "Research And Development Tax Credit Receivable [Member]", "terseLabel": "R&D Tax Credit Receivable [Member]" } } }, "localname": "ResearchAndDevelopmentTaxCreditReceivableMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "svra_ResearchAndDevelopmentTaxCreditsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development tax credits receivable.", "label": "Research And Development Tax Credits Receivable", "terseLabel": "Research and development tax credits receivable" } } }, "localname": "ResearchAndDevelopmentTaxCreditsReceivable", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "svra_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risks and uncertainties.", "label": "Risks And Uncertainties Policy [Text Block]", "terseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "svra_RoyaltyPercentOnNetSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty percent on net sale.", "label": "Royalty Percent On Net Sale", "terseLabel": "Royalty percent on net sale" } } }, "localname": "RoyaltyPercentOnNetSale", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_SalesCommissionsInFixedPercentageOfGrossProceedsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales commissions in fixed percentage of gross proceeds per share.", "label": "Sales Commissions In Fixed Percentage Of Gross Proceeds Per Share", "terseLabel": "Sales commissions in fixed percentage of gross proceeds per share" } } }, "localname": "SalesCommissionsInFixedPercentageOfGrossProceedsPerShare", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "svra_SavaraApSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Savara ApS.", "label": "Savara Ap S [Member]", "terseLabel": "Savara ApS [Member]" } } }, "localname": "SavaraApSMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "svra_SavaraAustraliaPtyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Savara australia pty limited.", "label": "Savara Australia Pty Limited [Member]", "terseLabel": "Savara Australia Pty Limited [Member]" } } }, "localname": "SavaraAustraliaPtyLimitedMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "svra_ScheduleOfCommonStockReservedForIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for issuance.", "label": "Schedule Of Common Stock Reserved For Issuance Table [Text Block]", "terseLabel": "Company's Shares of Common Stock Reserved for Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "svra_ScheduleOfNetProceedsFromPrivatePlacementTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of net proceeds from private placement.", "label": "Schedule Of Net Proceeds From Private Placement Table [Text Block]", "terseLabel": "Summary of Net Proceeds from Private Placement" } } }, "localname": "ScheduleOfNetProceedsFromPrivatePlacementTableTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "svra_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodInterval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award award vesting period interval.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Interval", "terseLabel": "Vesting interval period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodInterval", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term", "terseLabel": "Stock Options, Weighted-Average Remaining Contractual Years, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "durationItemType" }, "svra_SharesIssuedToUnderwriters": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued to underwriters.", "label": "Shares Issued To Underwriters", "terseLabel": "Common stock, shares issued to underwriters" } } }, "localname": "SharesIssuedToUnderwriters", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "svra_ShortTermInvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term investments fair value disclosure.", "label": "Short Term Investments Fair Value Disclosure [Abstract]", "terseLabel": "Short-term investments:" } } }, "localname": "ShortTermInvestmentsFairValueDisclosureAbstract", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "svra_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon Valley Bank.", "label": "Silicon Valley Bank [Member]", "terseLabel": "Silicon Valley Bank [Member]" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfMilestoneWarrantsNet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares issuance of common stock upon exercise of milestone warrants net.", "label": "Stock Issued During Period Shares Issuance Of Common Stock Upon Exercise Of Milestone Warrants Net", "terseLabel": "Issuance of common stock upon exercise of Milestone Warrants, net, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockUponExerciseOfMilestoneWarrantsNet", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "svra_StockIssuedDuringPeriodSharesLicensingOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, licensing of assets.", "label": "Stock Issued During Period Shares Licensing Of Assets", "terseLabel": "Issuance of common stock for licensing of assets, shares" } } }, "localname": "StockIssuedDuringPeriodSharesLicensingOfAssets", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "svra_StockIssuedDuringPeriodSharesStockWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares Stock Warrants Exercised.", "label": "Stock Issued During Period Shares Stock Warrants Exercised", "terseLabel": "Issuance of common stock upon exercise of stock warrants, net, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "svra_StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfMilestoneWarrantsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value issuance of common stock upon exercise of milestone warrants net.", "label": "Stock Issued During Period Value Issuance Of Common Stock Upon Exercise Of Milestone Warrants Net", "terseLabel": "Issuance of common stock upon exercise of Milestone Warrants, net" } } }, "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfMilestoneWarrantsNet", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "svra_StockIssuedDuringPeriodValueLicensingOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period, value, licensing of assets.", "label": "Stock Issued During Period Value Licensing Of Assets", "terseLabel": "Issuance of common stock for licensing of assets" } } }, "localname": "StockIssuedDuringPeriodValueLicensingOfAssets", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "svra_StockIssuedDuringPeriodValueStockWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock warrants exercised.", "label": "Stock Issued During Period Value Stock Warrants Exercised", "terseLabel": "Issuance of common stock upon exercise of stock warrants, net" } } }, "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "svra_SubleaseExpiryMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease expiry month and year.", "label": "Sublease Expiry Month And Year", "terseLabel": "Sublease expiry month and year" } } }, "localname": "SubleaseExpiryMonthAndYear", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "svra_SummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of net proceeds after deducting underwriting discounts commissions and offering expenses.", "label": "Summary Of Net Proceeds After Deducting Underwriting Discounts Commissions And Offering Expenses Table [Text Block]", "terseLabel": "Summary of Net Proceeds after Deducting Underwriting Discounts Commissions and Offering Expenses" } } }, "localname": "SummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesTableTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "svra_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "svra_TXLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TX lease.", "label": "T X Lease [Member]", "terseLabel": "TX Lease" } } }, "localname": "TXLeaseMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_TaxCreditCarryForwardsExpirationBeginningYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carry forwards expiration beginning year.", "label": "Tax Credit Carry Forwards Expiration Beginning Year", "terseLabel": "Tax credit carry forwards expiration beginning year" } } }, "localname": "TaxCreditCarryForwardsExpirationBeginningYear", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "svra_TaxCreditIncome": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax credit income.", "label": "Tax Credit Income", "terseLabel": "Tax credit income" } } }, "localname": "TaxCreditIncome", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "svra_TaxCreditReceivablePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit receivable.", "label": "Tax Credit Receivable Policy [Text Block]", "terseLabel": "Tax Credit Receivable" } } }, "localname": "TaxCreditReceivablePolicyTextBlock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "svra_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_TerminationOtherThanForCauseDeathOrDisabilityOrResignationForGoodReasonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination other than for cause death or disability or resignation for good reason.", "label": "Termination Other Than For Cause Death Or Disability Or Resignation For Good Reason [Member]", "terseLabel": "Termination Other Than for Cause Death or Disability or Resignation for Good Reason [Member]" } } }, "localname": "TerminationOtherThanForCauseDeathOrDisabilityOrResignationForGoodReasonMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_TwoThousandAndEightStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and eight stock option plan.", "label": "Two Thousand And Eight Stock Option Plan [Member]", "terseLabel": "2008 Stock Option Plan [Member]" } } }, "localname": "TwoThousandAndEightStockOptionPlanMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_TwoThousandAndFifteenOmnibusIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Omnibus incentive plan.", "label": "Two Thousand And Fifteen Omnibus Incentive Plan [Member]", "terseLabel": "2015 Omnibus Incentive Option Plan [Member]" } } }, "localname": "TwoThousandAndFifteenOmnibusIncentivePlanMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_TwoThousandAndTwentyOnePreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Pre funded Warrants.", "label": "Two Thousand And Twenty One Pre Funded Warrants [Member]", "terseLabel": "2021 Pre-funded Warrants [Member]" } } }, "localname": "TwoThousandAndTwentyOnePreFundedWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "svra_TwoThousandEightStockOptionPlanAndTwoThousandFifteenOmnibusIncentiveOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eight stock option plan and two thousand fifteen omnibus incentive option plan.", "label": "Two Thousand Eight Stock Option Plan And Two Thousand Fifteen Omnibus Incentive Option Plan [Member]", "terseLabel": "2008 Plan and 2015 Plan [Member]" } } }, "localname": "TwoThousandEightStockOptionPlanAndTwoThousandFifteenOmnibusIncentiveOptionPlanMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "domainItemType" }, "svra_TwoThousandSeventeenPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen pre-funded warrants.", "label": "Two Thousand Seventeen Pre Funded Warrants [Member]", "terseLabel": "2017 Pre-Funded Warrants [Member]" } } }, "localname": "TwoThousandSeventeenPreFundedWarrantsMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "svra_TwoThousandTwentyOneInducementEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one inducement equity incentive plan.", "label": "Two Thousand Twenty One Inducement Equity Incentive Plan [Member]", "terseLabel": "2021 Inducement Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandTwentyOneInducementEquityIncentivePlanMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_UnamortizedEndOfTermCharge": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unamortized end of term charge.", "label": "Unamortized End Of Term Charge", "negatedLabel": "Unamortized end of term charge" } } }, "localname": "UnamortizedEndOfTermCharge", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "svra_UpfrontCashPaymentPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront cash payment payable.", "label": "Upfront Cash Payment Payable", "terseLabel": "Upfront cash payment" } } }, "localname": "UpfrontCashPaymentPayable", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "svra_UpfrontPaymentCommonStockIssuedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payment common stock issued value.", "label": "Upfront Payment Common Stock Issued Value", "terseLabel": "Upfront payment value of common stock issued" } } }, "localname": "UpfrontPaymentCommonStockIssuedValue", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "svra_UpfrontPaymentCommonStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upfront payment common stock shares issued.", "label": "Upfront Payment Common Stock Shares Issued", "terseLabel": "Upfront payment common stock shares issued" } } }, "localname": "UpfrontPaymentCommonStockSharesIssued", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "svra_ValuationAllowanceDeferredTaxAssetDueToForeignTransalationAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Valuation allowance deferred tax asset due to foreign transalation adjustments.", "label": "Valuation Allowance Deferred Tax Asset Due to Foreign Transalation Adjustments", "terseLabel": "Foreign translation adjustments" } } }, "localname": "ValuationAllowanceDeferredTaxAssetDueToForeignTransalationAdjustments", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_ValuationAllowanceDeferredTaxAssetIncreaseByOffsetAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation allowance deferred tax asset increase by offset amount.", "label": "Valuation Allowance Deferred Tax Asset Increase by Offset Amount", "terseLabel": "Valuation allowance offset amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetIncreaseByOffsetAmount", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "svra_WarrantRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Repurchase.", "label": "Warrant Repurchase [Member]", "terseLabel": "Warrant Repurchase [Member]" } } }, "localname": "WarrantRepurchaseMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "svra_WarrantToPurchaseOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to purchase of common stock.", "label": "Warrant To Purchase Of Common Stock", "terseLabel": "Warrant to purchase of common stock" } } }, "localname": "WarrantToPurchaseOfCommonStock", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "svra_WarrantsAcquiredInMergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants acquired in merger.", "label": "Warrants Acquired In Merger [Member]", "terseLabel": "Warrants Acquired in April 2017 Merger [Member]" } } }, "localname": "WarrantsAcquiredInMergerMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "svra_WarrantsConvertedInConnectionWithMergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants converted in connection with merger.", "label": "Warrants Converted In Connection With Merger [Member]", "terseLabel": "Warrants Converted In Connection With April 2017 Merger [Member]" } } }, "localname": "WarrantsConvertedInConnectionWithMergerMember", "nsuri": "http://www.savarapharma.com/20221231", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r470", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "Accounting Standards Update 2019-12 [Member]", "terseLabel": "ASU 2019-12 [Member]" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "ASU 2020-06 [Member]" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r699" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r57" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization on premium to short-term investments, net", "terseLabel": "Amortization on premium to short-term investments, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r88", "r198" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r205", "r206", "r207", "r209", "r217", "r218", "r716" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Unrealized Gain (Loss) on ST Investments [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income Loss [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r34", "r35", "r36", "r203", "r632", "r644", "r648" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r216", "r217", "r535", "r536", "r537", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r33", "r36", "r142", "r566", "r639", "r640", "r716", "r717", "r718", "r723", "r724", "r725" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r32", "r36", "r142", "r217", "r218", "r536", "r537", "r538", "r539", "r540", "r716" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Exchange Translation Adjustment [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r9" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r448", "r449", "r450", "r723", "r724", "r725", "r789" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r242", "r243", "r244", "r245", "r255", "r303", "r304", "r316", "r317", "r318", "r319", "r321", "r322", "r448", "r449", "r450", "r470", "r471", "r472", "r473", "r484", "r485", "r486", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r542", "r543", "r547", "r548", "r549", "r550", "r561", "r562", "r563", "r564", "r565", "r566", "r610", "r611", "r612", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Repurchase of shares for minimum tax withholdings" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r123", "r124", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r96", "r103", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Incremental cost due to modification of detachable warrants previously issued with debt instrument" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r442" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r40", "r374", "r544", "r719" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r690", "r731" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset Backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r159", "r178", "r201", "r231", "r284", "r293", "r297", "r311", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r492", "r496", "r521", "r699", "r746", "r747", "r800" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r194", "r204", "r231", "r311", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r492", "r496", "r521", "r699", "r746", "r747", "r800" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r73" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r74" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r307", "r328" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r72", "r306", "r328", "r627" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-sale, Total", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r71", "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Short-term investments", "totalLabel": "Debt Securities, Available-for-sale, Current, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r145", "r147" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r58", "r196", "r667" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r53", "r58", "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r53", "r150" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Deposits insured by FDIC limit" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r188", "r189", "r241", "r303", "r304", "r312", "r313", "r314", "r316", "r317", "r470", "r484", "r485", "r498", "r501", "r502", "r512", "r522", "r524", "r525", "r526", "r529", "r530", "r542", "r546", "r547", "r548", "r549", "r561", "r562", "r610", "r611", "r637", "r638" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r188", "r189", "r303", "r304", "r312", "r313", "r314", "r316", "r317", "r470", "r484", "r485", "r486", "r498", "r501", "r502", "r503", "r506", "r512", "r522", "r524", "r525", "r526", "r529", "r530", "r542", "r546", "r547", "r548", "r549", "r561", "r562", "r610", "r611", "r637", "r638", "r726" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": { "auth_ref": [ "r192", "r241", "r304", "r312", "r315", "r318", "r471", "r486", "r498", "r503", "r506", "r512", "r523", "r524", "r527", "r528", "r530", "r543", "r546", "r548", "r549", "r612", "r637", "r638" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was early adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]", "terseLabel": "Change in accounting principle, accounting standards update, early adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r242", "r254", "r305", "r320", "r474" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants per share", "verboseLabel": "Exercise Price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class Of Warrant Or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants issued", "terseLabel": "Warrants issued to purchase shares of common stock", "verboseLabel": "Shares Underlying Outstanding Warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class Of Warrant Or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfOutstandingWarrantsForCompanySCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r487", "r488", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License Agreement" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r166", "r184" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r92", "r650" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Manufacturing and Other Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total shares reserved", "verboseLabel": "Aggregate number of common stock" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r723", "r724", "r789" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common stock authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySCommonStockDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r103" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCompanySCommonStockDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r699" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "verboseLabel": "Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2022 and 2021, respectively; 114,046,345 and 114,036,892 shares issued and outstanding as of December 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r37", "r212", "r214", "r219", "r628", "r633" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r174", "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r140", "r672" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r690", "r692", "r811" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r722", "r784", "r786" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r722", "r784" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r134", "r468", "r477", "r722" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r722", "r784", "r786" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State provision for income taxes", "verboseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r99", "r229", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r368", "r375", "r376", "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt Facility" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacility" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r160", "r162", "r176", "r237", "r352", "r353", "r354", "r355", "r356", "r358", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r545", "r682", "r683", "r684", "r685", "r686", "r720" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate, basis spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r162", "r176", "r379" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total future minimum payments" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "auth_ref": [ "r26", "r172" ], "lang": { "en-us": { "role": { "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format.", "label": "Debt Instrument, Date of First Required Payment", "terseLabel": "Debt instrument, date of first required payment" } } }, "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r152", "r154", "r352", "r545", "r683", "r684" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount", "verboseLabel": "Insured deposits" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "End of term charge" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r26", "r172" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Frequency of principal plus interest repayment period", "verboseLabel": "Interest payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r22", "r152", "r371" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeEnd1": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date Range, End", "terseLabel": "Debt instrument, maturity rate range, end" } } }, "localname": "DebtInstrumentMaturityDateRangeEnd1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r26", "r237", "r352", "r353", "r354", "r355", "r356", "r358", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r545", "r682", "r683", "r684", "r685", "r686", "r720" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r24", "r172" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt instrument payment description" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r151", "r154", "r751" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Debt discount related to warrants", "totalLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r732" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "terseLabel": "Realized gains or losses on investments", "totalLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss), Total" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Major Security Type of Investments" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r722", "r785", "r786" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 0.0, "parentTag": "svra_DeferredFederalForeignIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedLabel": "Federal tax benefit related to deferred tax liability", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r153", "r751" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Debt issuance costs", "totalLabel": "Debt Issuance Costs, Net, Total" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r134", "r722", "r785" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 2.0, "parentTag": "svra_DeferredFederalForeignIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r4", "r5", "r161", "r175", "r462" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "svra_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r722", "r785", "r786" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": 1.0, "parentTag": "svra_DeferredFederalForeignIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r463" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "svra_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r132", "r783" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Section 174 research and development expenses" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r132", "r783" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r132", "r783" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r132", "r783" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Foreign net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r132", "r783" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r130", "r132", "r783" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Credit carryforwards", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total", "verboseLabel": "Research and orphan drug tax credit carry forwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r130", "r132", "r783" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "State research and development tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r464" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r126", "r782" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred taxes", "totalLabel": "Deferred Tax Liabilities, Net, Total" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r132", "r783" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r132", "r783" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "terseLabel": "Prepaid assets" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r56", "r86" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r412", "r443", "r444", "r447", "r452", "r694" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r220", "r246", "r247", "r248", "r249", "r250", "r256", "r259", "r267", "r268", "r269", "r273", "r510", "r511", "r629", "r634", "r676" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share Basic [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r220", "r246", "r247", "r248", "r249", "r250", "r259", "r267", "r268", "r269", "r273", "r510", "r511", "r629", "r634", "r676" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r63", "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r270", "r271", "r272", "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r791" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r780", "r787" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r779" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Total compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options Outstanding [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r103", "r190", "r216", "r217", "r218", "r238", "r239", "r240", "r243", "r251", "r253", "r275", "r319", "r397", "r448", "r449", "r450", "r472", "r473", "r509", "r535", "r536", "r537", "r538", "r539", "r540", "r566", "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r513", "r514", "r519" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r366", "r401", "r402", "r403", "r404", "r405", "r406", "r514", "r580", "r581", "r582", "r683", "r684", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r513", "r514", "r515", "r516", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r366", "r401", "r406", "r514", "r580", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r366", "r401", "r406", "r514", "r581", "r683", "r684", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r366", "r401", "r402", "r403", "r404", "r405", "r406", "r514", "r582", "r683", "r684", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Fair value, assets, transfers into level 3, amount" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "terseLabel": "Fair value, assets, transfers out of level 3, amount" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r366", "r401", "r402", "r403", "r404", "r405", "r406", "r580", "r581", "r582", "r683", "r684", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r518", "r520" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r308", "r309", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r377", "r394", "r499", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r679", "r734", "r735", "r736", "r812", "r813", "r814", "r815", "r816", "r817", "r818" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r333", "r334", "r335", "r336", "r609", "r613" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r83", "r85" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authorities [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "auth_ref": [ "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.", "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value", "terseLabel": "Foreign exchange derivatives not designated as hedging instruments" } } }, "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r531", "r532", "r533", "r534" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Foreign currency loss", "terseLabel": "Foreign currency exchange loss", "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r56", "r97", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Extinguishment Of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r199", "r332", "r626", "r681", "r699", "r739", "r740" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "totalLabel": "Goodwill, Total" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r82", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Acquired In-Process Research and Development" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r719", "r741" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Impairment of IPR&D" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "IPR&D [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r232", "r478" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r38", "r157", "r167", "r186", "r284", "r292", "r296", "r298", "r630", "r678" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Total" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r232", "r478" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r233", "r457", "r460", "r467", "r475", "r479", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r781" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Expense", "terseLabel": "Interest and penalties related to income taxes", "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r234", "r252", "r253", "r283", "r455", "r476", "r480", "r635" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Total income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r215", "r453", "r454", "r460", "r461", "r466", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r780" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r780" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Impact of foreign operations" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r456" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax benefit computed at federal statutory tax rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r780" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount", "terseLabel": "Orphan drug & research credit expense disallowance" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r780" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r780" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedLabel": "Orphan drug & research credits generated" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r55" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r223", "r226", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (\"IRS\") [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r310", "r809" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Short-term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r81", "r158", "r171", "r187", "r666" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Short-term Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r795" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r795" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r796" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost and Other Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r797" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturity Analysis of Annual Undiscounted Cash Flows Reconciled to Carrying Value of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r560" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Present value of remaining lease payments", "totalLabel": "Total future minimum lease payments", "verboseLabel": "Operating lease, liability" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r560" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r560" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r560" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r560" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r794" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r231", "r311", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r493", "r496", "r497", "r521", "r677", "r746", "r800", "r801" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r163", "r181", "r699", "r721", "r737", "r790" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r195", "r231", "r311", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r493", "r496", "r497", "r521", "r699", "r746", "r800", "r801" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line Of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r16", "r720" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line Of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r162", "r179", "r365", "r380", "r683", "r684" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail2": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Current portion of long-term debt", "terseLabel": "Current portion of long-term debt", "totalLabel": "Long-term Debt, Current Maturities, Total" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r94", "r237", "r370" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 0.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r94", "r237", "r370" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r94", "r237", "r370" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r94", "r237", "r370" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r202" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail2": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "totalLabel": "Long-term Debt, Excluding Current Maturities, Total" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityCarryingValueAndFutureMinimumPaymentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Total manufacturing and other commitments" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureCommitmentsScheduleOfManufacturingCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-Term Purchase Commitment [Table Text Block]", "terseLabel": "Schedule of Manufacturing, Development, and Other Contingent Milestone Payments" } } }, "localname": "LongTermPurchaseCommitmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r26", "r95" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r225" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r225" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r53", "r54", "r57" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Cash from operations", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r39", "r57", "r168", "r185", "r193", "r210", "r213", "r218", "r231", "r242", "r246", "r247", "r248", "r249", "r252", "r253", "r265", "r284", "r292", "r296", "r298", "r311", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r511", "r521", "r678", "r746" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r246", "r247", "r248", "r249", "r256", "r257", "r266", "r269", "r284", "r292", "r296", "r298", "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r258", "r261", "r262", "r263", "r264", "r266", "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total", "verboseLabel": "Undistributed earnings and net loss attributable to common stockholders, basic and diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.", "label": "Open Tax Year", "terseLabel": "Open tax year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r284", "r292", "r296", "r298", "r678" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r552" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease, liability", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Operating lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfMaturityAnalysisOfAnnualUndiscountedCashFlowsReconciledToCarryingValueOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r552" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease, liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r552" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease, liability, non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r554", "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash outflows from operating leases", "verboseLabel": "Annual minimum lease payents" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfLeaseCostAndOtherInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease, right-of -use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r719" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r559", "r698" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Discounted using incremental borrowing rate", "verboseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfLeaseCostAndOtherInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r558", "r698" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in months) - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsScheduleOfLeaseCostAndOtherInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r200" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r31" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Loss on foreign currency translation", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "verboseLabel": "Foreign exchange translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r138", "r139", "r141", "r211", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Change", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r205", "r208" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on short-term investments", "verboseLabel": "Unrealized gain (loss) on short-term investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense), net:" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Non-currentAssets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "auth_ref": [ "r48" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.", "label": "Payments for Repurchase of Warrants", "negatedLabel": "Repurchase of outstanding pre-funded warrants", "terseLabel": "Repurchase of outstanding pre-funded warrants" } } }, "localname": "PaymentsForRepurchaseOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "terseLabel": "Prepayment fee" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "terseLabel": "Payment of debt issuance cost" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r52" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails": { "order": 1.0, "parentTag": "svra_NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r44", "r70", "r221" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of available-for-sale securities, net" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r45" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r7", "r381" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r715" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r668", "r680", "r738" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r47" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from long-term debt, net", "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Issuance of securities in private financing, net", "verboseLabel": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Gross proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross cash proceeds from sale of equity securities", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r70", "r221", "r222" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Maturity of available-for-sale securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r43", "r70", "r221" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Sale of available-for-sale securities, net" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r46", "r121" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r193", "r210", "r213", "r224", "r231", "r242", "r252", "r253", "r284", "r292", "r296", "r298", "r311", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r491", "r494", "r495", "r511", "r521", "r630", "r678", "r696", "r697", "r718", "r746" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r90", "r651", "r652", "r653" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r87", "r197" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r89", "r182", "r631", "r699" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r89", "r651", "r652" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r407", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r407", "r569", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r799" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r567", "r568", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r49" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayment of long-term debt", "terseLabel": "Repayment of outstanding amounts under Loan Agreement", "totalLabel": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r125" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Accrued Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Issued and nonvested RSUs [Member]", "verboseLabel": "RSUs [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r110", "r180", "r643", "r648", "r699" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r190", "r238", "r239", "r240", "r243", "r251", "r253", "r319", "r448", "r449", "r450", "r472", "r473", "r509", "r639", "r641" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r281", "r282", "r291", "r294", "r295", "r299", "r300", "r302", "r398", "r399", "r608" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Milestone revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Revenue from inception to date" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r673", "r674" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Net proceeds from sale of shares" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock, shares sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock, sale of stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r36", "r792", "r793" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r75", "r76", "r77", "r78", "r79", "r80", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Components of Benefit for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant Components of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciles Basic Earnings Per Share and Diluted Earnings Per Share of Common Stock" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r62", "r65", "r259", "r260", "r267" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of Expected Income Tax" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r119", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-based Compensation Expense included in Accompanying Statements of Operations and Comprehensive Loss" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value of Financial Instruments" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Components of Loss Before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Carrying Value and Future Minimum Payments" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r114", "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity and RSU Activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r409", "r411", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted to Employees" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r6", "r7", "r8", "r100", "r101", "r102", "r104", "r105", "r106", "r107", "r108", "r109", "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Summary of Company's Common Stock" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Outstanding Warrants for Company's Common Stock" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseIncludedInAccompanyingStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "RSUs, Shares Underlying Option Awards, Expired/cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "RSU's Weighted-Average Grant Date Fair Value, Expired/cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "RSUs, Shares Underlying Option Awards, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "RSU's Weighted-Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "RSU's, Shares Underlying Option Awards, Ending balance", "periodStartLabel": "RSU's, Shares Underlying Option Awards, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "RSU's Weighted-Average Grant Date Fair Value, Ending balance", "periodStartLabel": "RSU's Weighted-Average Grant Date Fair Value, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSUs, Shares Underlying Option Awards, Vested", "verboseLabel": "Issuance of common stock for settlement of RSUs, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "RSU's Weighted-Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Common stock available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Stock Options, Shares Underlying Option Awards, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Stock Options, Weighted-Average Exercise Price, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Stock Options, Aggregate Intrinsic Value, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Stock Options, Shares Underlying Option Awards, Expired/cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock Options, Shares Underlying Option Awards, Granted", "verboseLabel": "Options granted to purchase common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Stock Options, Aggregate Intrinsic Value Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Stock Options, Shares Underlying Option Awards, Outstanding at ending balance", "periodStartLabel": "Stock Options, Shares Underlying Option Awards, Outstanding at beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Stock Options, Weighted-Average Exercise Price, ending balance", "periodStartLabel": "Stock Options, Weighted-Average Exercise Price, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r434" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Stock Options, Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Stock Options, Shares Underlying Option Awards, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Stock Options, Weighted-Average Exercise Price, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options to purchase shares vested and outstanding." } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "One time, noncash incremental compensation expense net" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Stock Options, Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Stock Options, Weighted-Average Exercise Price, Expired/cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Stock Options, Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r416", "r435", "r436", "r437", "r438", "r441", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term", "verboseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAssumptionsUsedForEstimatingTheFairValueOfStockOptionsGrantedToEmployeesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Stock Options, Aggregate Intrinsic Value, Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Stock Options, Weighted-Average Remaining Contractual Years, Options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock Options, Weighted-Average Remaining Contractual Years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Stock Options, Weighted-Average Remaining Contractual Years, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of purchase price of shares of common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Repurchase of shares for minimum tax withholdings,shares" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r164", "r165", "r177", "r714" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments", "totalLabel": "Short-term Investments, Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r61", "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantPurchaseCommitmentDescription": { "auth_ref": [ "r28", "r166", "r183" ], "lang": { "en-us": { "role": { "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.", "label": "Purchase Commitment, Description", "terseLabel": "Agreement description" } } }, "localname": "SignificantPurchaseCommitmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r30", "r103", "r190", "r216", "r217", "r218", "r238", "r239", "r240", "r243", "r251", "r253", "r275", "r319", "r397", "r448", "r449", "r450", "r472", "r473", "r509", "r535", "r536", "r537", "r538", "r539", "r540", "r566", "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureShareholdersEquitySummaryOfNetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpensesDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityCompanySSharesOfCommonStockReservedForIssuanceDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfNetProceedsFromPrivatePlacementDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Other Comprehensive Income [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "StatementOfOtherComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r238", "r239", "r240", "r275", "r608" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Awards under Equity Incentive Plan [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r8", "r103", "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock and pre-funded warrants in public offering, net of offering costs,shares", "verboseLabel": "Common stock, shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture", "terseLabel": "Issuance of stock based awards" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r8", "r103", "r110", "r422" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Stock Options, Shares Underlying Option Awards, Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options, shares", "verboseLabel": "Options exercised to purchase common stock" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRSUActivityDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r7", "r8", "r103", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock and pre-funded warrants in public offering, net of offering costs", "verboseLabel": "Value of shares sold prior to amendment" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r30", "r103", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r69", "r699", "r721", "r737", "r790" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balances", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r136", "r137", "r143", "r190", "r191", "r217", "r238", "r239", "r240", "r243", "r251", "r319", "r397", "r448", "r449", "r450", "r472", "r473", "r509", "r535", "r536", "r540", "r566", "r640", "r641", "r721", "r737", "r790" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Total Accumulated Other Comprehensive Income (Loss)", "periodStartLabel": "Total Accumulated Other Comprehensive Income (Loss)", "totalLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityComponentsOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r112", "r230", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r397", "r500" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r541", "r575" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r541", "r575" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r541", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r541", "r575" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r574", "r576" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.savarapharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r308", "r309", "r377", "r394", "r499", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r734", "r735", "r736", "r812", "r813", "r814", "r815", "r816", "r817", "r818" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r242", "r243", "r244", "r245", "r255", "r303", "r304", "r316", "r317", "r318", "r319", "r321", "r322", "r448", "r449", "r450", "r470", "r471", "r472", "r473", "r484", "r485", "r486", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r542", "r543", "r547", "r548", "r549", "r550", "r561", "r562", "r563", "r564", "r565", "r566", "r610", "r611", "r612", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r788" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r808" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. Government Securities [Member]" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfMajorSecurityAndTypeOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r675", "r690", "r692", "r808" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Money Market Funds [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r66", "r67", "r68", "r276", "r277", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "(Decrease) increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValueAddedTaxReceivableCurrent": { "auth_ref": [ "r713" ], "calculation": { "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Value Added Tax Receivable, Current", "terseLabel": "VAT receivable" } } }, "localname": "ValueAddedTaxReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureDebtFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Warrants to Purchase Common Stock [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants and rights outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r258", "r269" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r256", "r269" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Weighted Average Number of Shares Outstanding, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.savarapharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareReconcilesBasicEarningsPerShareAndDilutedEarningsPerShareOfCommonStockDetail", "http://www.savarapharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r703": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r704": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r705": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r706": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r707": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r708": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r709": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r711": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r712": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }